In addition, emodin has pharmaceutical properties, such as anti-inflammatory and anti-tumor activities in mammalian cells by affecting the cellular NF-κB and MAPK (mitogen-activated protein kinase) signaling pathways (Huang et al., 2004; Wang et al., 2006; Xie et al., 2019). Here, NFKB1 is linked to neoplasm.